Hugo Chrost
CEO

The startup utilizes proprietary machine learning algorithms to create diagnostic-predictive digital biomarkers for neurodegenerative diseases. This technology provides healthcare professionals with accurate and early diagnostic tools, enhancing patient care and drug discovery processes.
Raised to date
$4.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Traditional pupil assessment relies on subjective methods or bulky, expensive devices, leading to inconsistent evaluations and delayed detection of neurological changes. This can hinder timely interventions and negatively impact patient outcomes, particularly in critical care settings where frequent monitoring is essential.
Solvemed provides an AI-powered pupillometry system that transforms a smartphone into a Class I medical device for objective and automated pupil light reflex testing. The system enables accurate measurement of pupil size and reactivity, providing clinicians with quantitative data to support neurological assessments. By replacing traditional penlights and pupilometers with a software-based solution, Solvemed streamlines clinical workflows, reduces costs, and facilitates continuous neurological monitoring at the point of care. The system integrates with electronic medical records (EMR) for seamless data transfer and improved decision-making.
The primary target audience includes healthcare professionals in critical care, anesthesiology, neurology, nursing, ophthalmology, and neuro-ophthalmology, as well as clinical researchers focused on neurological disorders.